Anzeige
Mehr »
Samstag, 01.11.2025 - Börsentäglich über 12.000 News
Der menschliche Genius hinter den Maschinen: Telescope Innovations und der Aufstieg der autonomen Wissenschaft
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12CNT | ISIN: SE0003656834 | Ticker-Symbol: M02
Stuttgart
31.10.25 | 07:51
0,053 Euro
-2,91 % -0,002
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IZAFE GROUP AB Chart 1 Jahr
5-Tage-Chart
IZAFE GROUP AB 5-Tage-Chart
ACCESS Newswire
223 Leser
Artikel bewerten:
(1)

iZafe Group Board Members Acquire Shares

STOCKHOLM, SE / ACCESS Newswire / October 3, 2025 / iZafe Group (STO:IZAFE-B) - iZafe Group AB (publ.) announces that the company's board members have collectively acquired 156,000 B-shares in the company at an average price of approximately SEK 0.55 per share.

"The fact that the entire board has chosen to increase its ownership is a clear signal of our shared commitment and confidence in iZafe's strategy and future. We see great potential in the company's continued development and, through our investments, want to demonstrate that we fully support the path that has been set out," says Richard Wolff, Chairman of the Board of iZafe Group.

Contacts

Anders Segerström, Chief Executive Officer
E-mail: anders.segerstrom@izafegroup.com
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
David Bagares gata 3
111 38 Stockholm

E-mail: ir@izafegroup.com
www.izafegroup.com
eucaps.com/izafe-group

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution Pilloxa with the smart pillbox. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.

The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. The company's Certified Adviser is DNB Carnegie Investment Bank AB. Further information is available at www.izafegroup.com

Image Attachments

Finance

Attachments

iZafe Group Board Members Acquire Shares

SOURCE: iZafe Group



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/izafe-group-board-members-acquire-shares-1081308

© 2025 ACCESS Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.